What is HC Wainwright’s Forecast for PTGX Q2 Earnings?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Protagonist Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.67) for the quarter, down from their previous forecast of ($0.65). HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at $0.93 EPS, FY2025 earnings at ($0.41) EPS, Q1 2026 earnings at $0.03 EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.41) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at $2.86 EPS.

A number of other research analysts have also issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and set a $58.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. Truist Financial lifted their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Tuesday, March 11th. BTIG Research set a $73.00 price target on Protagonist Therapeutics in a report on Monday, March 3rd. Wedbush restated an “outperform” rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a report on Friday, March 28th. Finally, BMO Capital Markets upped their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.44.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $44.27 on Monday. The stock has a market capitalization of $2.74 billion, a PE ratio of 16.64 and a beta of 2.65. Protagonist Therapeutics has a 12-month low of $27.00 and a 12-month high of $60.60. The firm has a 50 day simple moving average of $47.20 and a 200-day simple moving average of $42.67.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.31. The firm had revenue of $28.32 million during the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of hedge funds have recently modified their holdings of PTGX. Barclays PLC boosted its stake in Protagonist Therapeutics by 223.6% in the 3rd quarter. Barclays PLC now owns 126,995 shares of the company’s stock valued at $5,714,000 after buying an additional 87,755 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Protagonist Therapeutics by 127.2% in the 3rd quarter. Franklin Resources Inc. now owns 81,591 shares of the company’s stock worth $3,782,000 after acquiring an additional 45,674 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Protagonist Therapeutics by 3,099.4% during the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock valued at $14,437,000 after purchasing an additional 310,804 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Protagonist Therapeutics in the 4th quarter valued at $38,000. Finally, Assenagon Asset Management S.A. bought a new position in Protagonist Therapeutics in the 4th quarter valued at $2,016,000. 98.63% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Asif Ali sold 24,903 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the transaction, the chief financial officer now owns 62,821 shares of the company’s stock, valued at approximately $3,689,477.33. The trade was a 28.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now directly owns 540,260 shares of the company’s stock, valued at $20,627,126.80. This represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,532 shares of company stock valued at $3,665,786 over the last three months. 5.40% of the stock is currently owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.